|Articles|May 1, 2001

Postmenopausal estrogen therapy and ovarian cancer

Small patient numbers, weak associations, plus the mixed story in the observational studies complicate accurate interpretation of the latest epidemiologic study on ERT.

Newsletter

Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.

Subscribe

Related Content

Justin Drake, PhD, explains the Certitude Breast blood test for early breast cancer detection

ByJustin Drake, PhD

June 4th 2026

Clinical pearls into new postmenopausal guidelines from ACOG, with Susan Loeb-Zeitlin, MD, FACOG

Clinical pearls into ACOG's postmenopausal bleeding guidelines with Susan Loeb-Zeitlin, MD, FACOG

BySusan E. Loeb-Zeitlin, MD, FACOG

June 4th 2026

SMFM in midst of first annual High-Risk Pregnancy Awareness Week

ByJoshua Fitch, Senior Editor

June 3rd 2026

Nearly 18 million US women aged 45 to 64 overdue for cancer screening, study finds

ByJoshua Fitch, Senior Editor

June 3rd 2026

Individualized TRT demonstrates broad symptom improvements beyond sexual function

ByMelissa Loseke, DO

June 2nd 2026

Latest CME

Video

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Washington

Alison K. Conlin, MD; Neil M. Iyengar, MD

Video

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Wyoming & Montana

Yan Ji, MD; Neil M. Iyengar, MD

Video

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – North Carolina

Girish Kunapareddy, MD; Sara M. Tolaney, MD, MPH

Video

Addressing Healthcare Inequities: Detecting and Managing the Uncommon – Hemophilia in Women

Danielle Nance, MD; Kimberley Youkhana, MD

Postmenopausal estrogen therapy and ovarian cancer

Related Content

Justin Drake, PhD, explains the Certitude Breast blood test for early breast cancer detection

Clinical pearls into ACOG's postmenopausal bleeding guidelines with Susan Loeb-Zeitlin, MD, FACOG

SMFM in midst of first annual High-Risk Pregnancy Awareness Week

Nearly 18 million US women aged 45 to 64 overdue for cancer screening, study finds

Individualized TRT demonstrates broad symptom improvements beyond sexual function

Latest CME

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Washington

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Wyoming & Montana

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – North Carolina

Addressing Healthcare Inequities: Detecting and Managing the Uncommon – Hemophilia in Women

Trending on Contemporary OB/GYN

Acetaminophen remains first-line medication for pain, fever in pregnancy, SMFM says

Justin Drake, PhD, explains the Certitude Breast blood test for early breast cancer detection

Clinical pearls into ACOG's postmenopausal bleeding guidelines with Susan Loeb-Zeitlin, MD, FACOG

Nearly 18 million US women aged 45 to 64 overdue for cancer screening, study finds

Comorbidities associated with lower HRT uptake may reflect overcautious prescribing